KLRC1 and cancer: These anti-cancer therapies include the anti-KIR2DL-1, -2 and -3 antibody IPH2102/BMS-986015 (lirilumab), the anti-NKG2A antibody IPH2201 (monalizumab), and the anti-CD16 innate cell engager AFM13 [181].